What are the indications and recommendations for using the Myosure device in adult women with uterine fibroids or other intrauterine pathologies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Myosure Device: Indications and Recommendations

Primary Indication

The Myosure device is indicated for hysteroscopic removal of intrauterine pathology, specifically endometrial polyps and type 0 or type I submucosal fibroids, with optimal results for lesions ≤4 cm in diameter. 1, 2, 3

Specific Clinical Indications

Endometrial Polyps

  • The Myosure device achieves near-complete resection rates of 98-100% for endometrial polyps, making it the preferred hysteroscopic approach for these lesions 1, 2, 3
  • Effective for polyps causing abnormal uterine bleeding in both office and ambulatory surgical center settings 1

Submucosal Fibroids (Leiomyomas)

  • Type 0 and Type I submucosal fibroids between 1.5-4 cm are ideal candidates for Myosure resection 1, 2
  • Complete resection rates vary by fibroid characteristics:
    • 87% complete resection for fibroids ≤40 mm 2
    • Only 48% complete resection for fibroids >40 mm, requiring repeat procedures 2
    • 73.7% overall complete resection rate for leiomyomas compared to 98.1% for polyps 3

Type II Fibroids: A Critical Limitation

  • Type II submucosal fibroids (predominantly intramural with <50% intracavitary component) have significantly lower complete excision rates (OR = 1.8, p = 0.01) 3
  • These lesions may require alternative approaches such as laparoscopic or open myomectomy 4

Retained Products of Conception

  • 100% complete excision rate for retained products of conception, making this an excellent indication 2, 3

Clinical Outcomes and Efficacy

Symptom Improvement

  • Significant and durable improvement in quality of life metrics at 12 months post-procedure 1
  • Uterine Fibroid Symptom-Quality of Life (UFS-QOL) scores improved from baseline mean of 67.5 to 22.3 at 12 months (p < 0.01) 1
  • Health-Related Quality of Life (HRQOL) scores improved from 38.7 to 83.9 at 12 months (p < 0.01) 1
  • 76% of patients achieved complete symptom resolution 2

Reintervention Rates

  • 10% of patients required further surgery (repeat hysteroscopy or hysterectomy) 2
  • This is primarily due to incomplete resection of larger or Type II fibroids 2, 3

Setting and Safety Profile

Office-Based vs. Ambulatory Surgical Center

  • The Myosure device can be safely performed in both office-based settings and ambulatory surgical centers with equivalent outcomes 1, 3
  • 99% of patients would undergo the procedure again or recommend it, indicating high patient acceptability 3

Pain Management

  • 73% of patients report mild pain, 17% moderate pain, and only 7.3% severe pain during the procedure 3
  • This favorable pain profile supports office-based use without general anesthesia in selected patients 3

Safety

  • No intraoperative complications were reported in prospective studies 2
  • The device avoids risks associated with traditional electrosurgical resection, including thermal injury and fluid overload 4

Training and Learning Curve

  • 61% of procedures can be safely performed by trainees with similar clinical outcomes to senior clinicians 2
  • No statistically significant difference in outcomes when procedures performed by attending physicians versus residents for polyps 2
  • Leiomyomas are more likely to be completely resected by attending physicians or senior residents, though this did not affect overall clinical outcomes 2

Contraindications and Limitations

Size Limitations

  • Fibroids >4 cm have significantly reduced complete excision rates (OR = 1.6, p = 0.02) and should be considered for alternative treatments 3
  • Multiple procedures may be required for larger lesions 2

Anatomical Limitations

  • Type II fibroids with predominantly intramural components are poor candidates 3
  • Distorted uterine cavities or anatomical abnormalities incompatible with device insertion preclude use 5

Fertility Considerations

  • For women desiring pregnancy with submucosal fibroids <4 cm, hysteroscopic resection (including Myosure) is recommended regardless of symptoms 6
  • The device preserves the endometrium better than traditional resection techniques 1

Clinical Algorithm for Patient Selection

Proceed with Myosure if:

  • Endometrial polyps of any size causing symptoms 1, 3
  • Type 0 or Type I submucosal fibroids ≤4 cm 1, 2, 3
  • Retained products of conception 2, 3
  • Patient desires office-based or minimally invasive approach 3

Consider alternative approaches if:

  • Fibroids >4 cm (consider UAE, myomectomy, or MRgFUS) 4
  • Type II fibroids (consider laparoscopic/open myomectomy) 4, 3
  • Multiple large fibroids (consider UAE or myomectomy) 4
  • Concurrent adenomyosis requiring treatment (Myosure will not address this) 4

Common Pitfalls to Avoid

  • Do not attempt complete single-session resection of fibroids >4 cm—plan for staged procedures or alternative treatment 2, 3
  • Do not use Myosure as sole treatment for Type II fibroids—incomplete resection is likely 3
  • Do not overlook concurrent adenomyosis—this will not be treated by hysteroscopic morcellation and may require additional therapy 4
  • Ensure adequate preoperative imaging (transvaginal ultrasound with saline infusion sonohysterography or MRI) to accurately classify fibroid type and size 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.